DTC Review Will Cost Industry $83,000 Per Ad Under FDA’s Final PDUFA Plan

FDA expects to charge companies $83,000 per advertisement under a pre-review program included as part of the agency's proposal for renewal of the prescription drug user fee program

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet